Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof William Kemp

A/Prof William Kemp

Cardiovascular Risk and Fatty Liver Disease

Dr Ryan De Cruz

Dr Ryan De Cruz

Importance of Early & Effective Treatment of Mild to Moderate Acne

Prof Merlin Thomas

Prof Merlin Thomas

SGLT2s and Renal Protection

Dr Adam Nelson

Dr Adam Nelson

CV Medications – Practical Strategies to Improve Compliance

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023